Riluket50 mg

Riluket is indicated for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease. It is an FDA-approved, guideline-supported disease-modifying therapy shown to modestly prolong survival and/or extend the time to tracheostomy or mechanical ventilation in patients with ALS.

• Established/FDA-approved use: Treatment of ALS in adults, across clinical subtypes (bulbar-onset and limb-onset), typically initiated as soon as the diagnosis is confirmed.

Riluket does not reverse motor neuron damage that has already occurred, does not improve muscle strength or function, and is not a cure for ALS; its benefit is a modest extension of survival time. Riluket is not approved or indicated for other forms of motor neuron disease, general neuroprotection, or any condition outside ALS.

Each tablet of Riluzole contains Riluzole 50 mg as the active ingredient, along with pharmaceutically approved excipients. Riluzole is also available in some markets as an oral suspension (50 mg/10 mL) and as an orally disintegrating tablet, each formulated to deliver an equivalent 50 mg dose of Riluzole per unit.

Riluket is a benzothiazole-class, glutamate-modulating agent used specifically in the management of amyotrophic lateral sclerosis (ALS). It was one of the first agents shown in randomized controlled trials to extend survival in ALS patients and remains a standard-of-care disease-modifying option alongside supportive and symptomatic care.

Riluket is administered orally, generally on an empty stomach, and is available as conventional tablets, an oral suspension, and an orally disintegrating tablet, allowing flexibility for patients with swallowing difficulties (dysphagia), which are common in ALS.

Riluket belongs to the therapeutic class of glutamate-modulating / neuroprotective agents used in motor neuron disease. Chemically, Riluket is a benzothiazole derivative and is the prototype agent in this narrow drug class, which is specifically developed for ALS rather than general neurological or psychiatric use.

The precise mechanism by which Riluzole exerts its therapeutic effect in ALS is not completely established, but several complementary actions have been described:

• Inhibition of presynaptic glutamate release, reducing excitotoxic stimulation of motor neurons.
• Inactivation of voltage-dependent sodium channels, which may reduce excessive neuronal excitability.
• Interference with intracellular events that follow glutamate binding at excitatory amino acid receptors.

Through these actions, Riluzole is thought to reduce glutamate-mediated excitotoxic damage to motor neurons, which is believed to contribute to the progression of ALS. Riluzole is well absorbed orally (absorption is reduced by food), is extensively metabolized in the liver primarily via CYP1A2, and has an elimination half-life of approximately 9-15 hours.

Riluket should be taken consistently at the same times each day, at least 1 hour before or 2 hours after a meal, because food reduces its absorption. Tablets should be swallowed whole with water. If an oral suspension formulation of Riluket is used, shake well and measure the dose with the provided oral syringe. If an orally disintegrating tablet formulation is used, it should be placed on the tongue and allowed to disintegrate without water, which may benefit patients with swallowing difficulty. Do not crush conventional tablets unless directed by a physician or pharmacist.

• CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine): may increase plasma concentrations of Riluket, increasing the risk of adverse effects; use with caution.
• CYP1A2 inducers (e.g., rifampin, omeprazole, cigarette smoking): may decrease plasma concentrations of Riluket and reduce its effectiveness.
• Other hepatotoxic drugs or alcohol: concurrent use may increase the risk of liver injury; monitor liver function closely (see Precautions and Warnings for full detail).

Common side effects of Riluket include:

• Nausea and vomiting
• Asthenia (weakness/fatigue)
• Dizziness
• Abdominal pain and diarrhea
• Elevated liver enzymes (usually asymptomatic)
• Decreased lung function (spirometry changes)
• Oral paresthesia (with orally disintegrating tablet)

Less common but serious effects include severe hepatotoxicity, neutropenia, and interstitial lung disease (see Precautions and Warnings). Seek prompt medical attention for signs of liver injury (jaundice, dark urine, persistent nausea), unusual bleeding/infection, or new breathing difficulty.

Pregnancy: There are limited human data on the use of Riluket in pregnancy. Riluket should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Riluket passes into human breast milk. Because of the potential for serious adverse reactions in a breastfeeding infant, a decision should be made whether to discontinue breastfeeding or discontinue Riluket, taking into account the importance of treatment to the mother, in consultation with a physician.

• Hepatotoxicity: Riluket can cause drug-induced liver injury, including rare severe hepatitis. Liver function tests (ALT/AST, bilirubin) should be checked before starting treatment, monthly for the first 3 months, periodically thereafter, and if symptoms of liver dysfunction occur. Discontinue if transaminases rise markedly above the upper limit of normal or if jaundice develops.
• Neutropenia: Rare cases of severe neutropenia have been reported; advise patients to report fever or signs of infection promptly.
• Interstitial lung disease: Rare reports of interstitial lung disease, some severe; evaluate new respiratory symptoms promptly.
• Timing with food: Take consistently relative to meals (empty stomach) as food reduces absorption and may reduce effectiveness if timing is inconsistent.
• Driving/operating machinery: Riluket may cause dizziness; use caution with activities requiring alertness.
• Smoking: Cigarette smoking may reduce plasma levels of Riluket via CYP1A2 induction.

Limited data are available on Riluket overdose. Reported features have included neurological and psychiatric symptoms, and toxic encephalopathy has been described with very large ingestions. There is no specific antidote for Riluket overdose. If overdose is suspected, seek immediate medical attention or contact emergency services or a poison control center; treatment is supportive and symptomatic under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Hepatic impairment: Use with caution and close monitoring in mild-to-moderate hepatic impairment; contraindicated with markedly elevated baseline transaminases (see Contraindications).
• Renal impairment: Limited data; no well-established dose adjustment, use with caution.
• Elderly: No specific dose adjustment established; monitor as for general adult population, considering age-related organ function decline.
• Smokers: Plasma levels of Riluket may be reduced due to CYP1A2 induction from smoking.
• Pediatric patients: Safety and efficacy not established (see Pediatric Uses).

Riluket is intended for long-term, continuous use in ALS, generally for as long as the patient tolerates therapy and derives potential benefit, under ongoing physician supervision with periodic liver function monitoring. Treatment should not be stopped abruptly without medical advice; the decision to continue or discontinue is individualized based on tolerability, disease progression, and patient/caregiver goals of care.

Riluzole is classified as a benzothiazole derivative and glutamate-modulating (antiglutamatergic) neuroprotective agent, used specifically for amyotrophic lateral sclerosis.

Riluzole is believed to act by inhibiting presynaptic glutamate release, inactivating voltage-dependent sodium channels, and interfering with intracellular signaling triggered by glutamate binding at excitatory amino acid receptors. These combined actions reduce glutamate-mediated excitotoxicity, which is implicated in the progressive motor neuron degeneration seen in ALS.

C

The safety and efficacy of Riluket have not been established in pediatric patients. Amyotrophic lateral sclerosis is extremely rare in children, and Riluket is not indicated for pediatric use outside of specialist clinical judgment in rare confirmed pediatric ALS cases.